BiomX Inc

Contributing Author

Recent Articles by BiomX Inc

5 hours	BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review PHGE -29.79% GlobeNewswire
Nov-25	BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis PHGE GlobeNewswire
Nov-14	BiomX Inc. Announces 1-for-19 Reverse Stock Split PHGE GlobeNewswire
Nov-12	BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates PHGE GlobeNewswire
Nov-05	BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025 PHGE GlobeNewswire
Nov-04	BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections PHGE GlobeNewswire
Oct-17	BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways PHGE GlobeNewswire
Sep-04	BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference PHGE GlobeNewswire
Aug-19	BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis PHGE GlobeNewswire
Aug-13	BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates PHGE GlobeNewswire
Aug-06	BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 PHGE GlobeNewswire
Jul-14	BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis PHGE GlobeNewswire
Jul-08	BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis PHGE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.